24/7 Market News Snapshot 24 December, 2024 – Clearmind Medicine Inc. Common Shares (NASDAQ:CMND)

December 24, 2024

DENVER, Colo., 24 December, 2024 (247marketnews.com) – (NASDAQ:CMND) are discussed in this article.
Clearmind Medicine Inc. (CMND) is experiencing a remarkable surge in pre-market trading, with shares climbing to $2.106, marking a notable increase of 72.62% from the previous close of $1.220. The company has witnessed a significant trading volume of 3.17 million shares, signaling robust investor enthusiasm and confidence in its growth trajectory. This bullish momentum reflects heightened optimism among market participants regarding Clearmind’s advancements in psychedelic therapies and mental health solutions.

Contributing to this positive sentiment, Clearmind has secured Institutional Review Board (IRB) approval for its Phase I/IIa clinical trial of CMND-100, targeting alcohol use disorder (AUD). The trial will be conducted at a prominent medical institution under the guidance of Dr. Anahita Bassir Nia, a distinguished expert in psychiatry and addiction medicine. This approval represents a crucial step in Clearmind’s FDA-regulated clinical program, permitting the expansion of its multi-site trial to assess the safety, tolerability, and efficacy of its proprietary drug.

Dr. Adi Zuloff-Shani, CEO of Clearmind, emphasized the significance of this achievement, highlighting the urgent need for innovative treatment options in light of alcohol consumption’s contribution to 2.6 million deaths globally each year. Current AUD treatments often face challenges related to high costs and limited effectiveness, which Clearmind aims to address by developing solutions that target the root causes of alcohol cravings and consumption.

The forthcoming clinical trial is designed to generate essential data that will facilitate the progression of CMND-100 through the clinical pipeline. As a clinical-stage biotech firm dedicated to psychedelic-derived therapies, Clearmind is well-positioned to lead advancements in addressing significant health issues. Stakeholders are encouraged to monitor the company’s progress as it endeavors to transform the treatment landscape for AUD and deliver hope to those impacted by this widespread condition.

Related news for (CMND)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.